A study published in JAMA Psych showed that patients with alcohol use disorder who used GLP-1 agonists had a reduced risk for hospitalization due to alcohol use disorder. The study included 227,866 participants diagnosed with AUD from 2006 to 2021. Semaglutide and liraglutide were associated with lower risk for somatic hospitalization. Participants on semaglutide had the lowest risk for hospitalization due to AUD compared to non-use. The study’s limitations included its observational nature, with researchers calling for randomized clinical trials to confirm if GLP-1 agonists could effectively treat AUD and SUDs.
Source link
GLP-1 agonists semaglutide, liraglutide may help to treat alcohol use disorder
